Attributes | Values |
---|
rdf:type
| |
Description
| - Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF(V600E) gene. Aim: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the primary tumour with clinicopathological parameters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours. Subjects and methods: Retrospective analysis of the BRAF(V600E) mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlin, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors. Results: DNA was successfully extracted from 137 samples. The BRAF(V600E) mutation was detected in 78 cases (56.9 %). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR = 2.39 (95 %) CI 1.00-5.75, p = 0.052]. In the classic papillary variant, the BRAF(V600E) mutation was found significantly more often than in other PTC subtypes (p = 0.022). We did not confirm any significant association between the BRAF(V600E) mutation and other clinicopathological findings. Conclusion: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.
- Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF(V600E) gene. Aim: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the primary tumour with clinicopathological parameters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours. Subjects and methods: Retrospective analysis of the BRAF(V600E) mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlin, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors. Results: DNA was successfully extracted from 137 samples. The BRAF(V600E) mutation was detected in 78 cases (56.9 %). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR = 2.39 (95 %) CI 1.00-5.75, p = 0.052]. In the classic papillary variant, the BRAF(V600E) mutation was found significantly more often than in other PTC subtypes (p = 0.022). We did not confirm any significant association between the BRAF(V600E) mutation and other clinicopathological findings. Conclusion: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC. (en)
|
Title
| - Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma
- Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma (en)
|
skos:prefLabel
| - Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma
- Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma (en)
|
skos:notation
| - RIV/00216208:11120/14:43909267!RIV15-MSM-11120___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - I, O, P(ED0030/01/01), P(LM2010004), V
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/14:43909267
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - neck node metastases; clinical and pathological parameters; BRAF(V600E) mutation; papillary carcinoma (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - DE - Spolková republika Německo
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Experimental and Clinical Endocrinology & Diabetes
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
http://localhost/t...ganizacniJednotka
| |